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b-catenin is involved in both cell – cell interactions and
wnt pathway – dependent cell fate determination through
its interactions with E-cadherin and TCF/LEF transcrip-
tion factors, respectively. Cytoplasmic/nuclear levels of
b-catenin are important in regulated transcriptional
activation of TCF/LEF target genes. Normally, these
levels are kept low by proteosomal degradation of b-
catenin through Axin1- and APC-dependent phosphoryla-
tion by CKI and GSK-3b. Deregulation of b-catenin
degradation results in its aberrant accumulation, often
leading to cancer. Accordingly, aberrant accumulation of
b-catenin is observed at high frequency in many cancers.
This accumulation correlates with either mutational
activation of CTNNB1 (b-catenin) or mutational inacti-
vation of APC and Axin1 genes in some tumors.
However, there are many tumors that display b-catenin
accumulation in the absence of a mutation in these genes.
Thus, there must be additional sources for aberrant b-
catenin accumulation in cancer cells. Here, we provide
experimental evidence that wild-type b-catenin accumu-
lates in hepatocellular carcinoma (HCC) cells in
association with mutational inactivation of p53 gene.
We also show that worldwide p53 and b-catenin mutation
rates are inversely correlated in HCC. These data suggest
that inactivation of p53 is an important cause of aberrant
accumulation of b-catenin in cancer cells.
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Introduction
The protein product of b-catenin gene plays a dual
role, acting as a structural component of cell – cell
adherence junctions, as well as a nuclear transcriptional
co-activator when complexed with members of the T-
cell factor/lymphoid enhancer factor (TCF/LEF)
family of DNA binding proteins (reviewed in Polakis,
2000). Transcription co-activator function of b-catenin
is regulated in a concentration-dependent manner
based on a controlled proteosome-dependent degrada-
tion system. Under cellular conditions, which do not
require TCF/LEF-dependent transcription, b-catenin is
targeted to the proteosome by casein kinase 1(CKI)-
and glycogen synthase kinase-3b (GSK-3b)-mediated
phosphorylation of its N-terminally located serine/
theronine residues (Polakis, 2000; Amit et al., 2002; Liu
et al., 2002). This phosphorylation occurs in a multi-
molecular complex, which contains APC and Axin1
tumor suppressor proteins, in addition to b-catenin and
CKI/GSK-3B dual-kinase system. The Wnt signaling is
the major known activator of b-catenin and this is
achieved by wnt-dependent inhibition of GSK-3b
kinase activity leading to accumulation of b-catenin
protein in target cells (Barker et al., 2000; Polakis,
2000).
Cytoplasmic and/or nuclear accumulation of b-
catenin is a highly frequent event affecting various
cancers including colorectal, lung, breast, cervix
cancers, melanoma, HCC and hepatoblastoma (Candi-
dus et al., 1996; Rimm et al., 1999; Chung, 2000;
Johnsson et al., 2000; Lin et al., 2000; Park et al., 2001;
Shinohara et al., 2001; Ueda et al., 2001; Hommura et
al., 2002; Inagawa et al., 2002). In colorectal cancers,
b-catenin accumulation is often associated with muta-
tional inactivation of APC gene, which affects almost
80% of these tumors (Kinzler and Vogelstein, 1998).
About 50% of colorectal cancers with wild-type APC
gene display oncogenic mutations affecting b-catenin
directly (Sparks et al., 1998). In hepatoblastomas, APC
mutations are rare, but these tumors display b-catenin
mutations at very high frequency (Koch et al., 1999;
Wei et al., 2000; Park et al., 2001). In other tumors,
aberrant accumulation of b-catenin protein is not
always associated with a mutation affecting these
genes. For example, it has been recently reported that
8 – 13% of HCCs are affected by a b-catenin mutation,
whereas 33 – 69% of these tumors display aberrant b-
catenin protein accumulation (Hsu et al., 2000;
Devereux et al., 2001; Wong et al., 2001). Among
other candidate genes, Axin1 was found to be mutated
in a small fraction (7 – 9%) of HCCs (Satoh et al.,
2000; Laurent-Puig et al., 2001), whereas APC
mutations were exceptional, if not absent (Huang et
al., 1999). Thus, it is estimated that between 35 and
80% of HCCs, the aberrant b-catenin accumulation is
not associated with a mutation affecting b-catenin,
Axin1 or APC gene. Aberrant accumulation of b-
catenin protein without associated mutations on b-
catenin, APC or Axin1 gene is not limited to HCC,
since mutations affecting these genes are absent or
exceptional in several other common malignancies suchReceived 15 May 2002; revised 22 July 2002; accepted 30 July 2002
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as cancers of the breast, lung and cervix, and
melanomas (Candidus et al., 1996; Rimm et al., 1999;
Lin et al., 2000; Ueda et al., 2001; Shinohara et al.,
2001; Hommura et al., 2002). Thus, in many tumors,
aberrant accumulation of b-catenin cannot be linked to
a known mutation affecting wnt pathway, raising the
possibility that mutations affecting the genes involved
in other pathways may also contribute to aberrant
accumulation of b-catenin in cancer cells.
Here, we report on aberrant accumulation of wild-
type b-catenin protein in association with p53 gene
mutation in HCC cells. In addition, ectopic expression
of mutant p53 in two different HCC cell lines resulted
in the up-regulation of wild-type b-catenin levels.
Based on previously published and our own data, we
also show that there is an inverse relationship between
worldwide distribution of p53 and b-catenin mutation
rates in HCCs. These observations suggest that p53
mutations may lead to aberrant accumulation of b-
catenin protein in HCC, thereby reducing a selective
pressure for b-catenin mutation during hepatocellular
carcinogenesis.
Results
Comparative analysis of b-catenin and p53 genes in
hepatocellular carcinoma cell lines
A total of 12 HCC cell lines were analysed for b-
catenin gene mutation by SSCP, fragment length
analysis and nucleic acid sequencing. Heterozygous b-
catenin gene mutations were identified in two cell lines
(Table 1). HepG2 cell line displayed an interstitial
deletion leading to a truncated protein product lacking
amino acids from 25 to 140 (sequencing data not
shown, see later for genomic deletion), whereas
SNU398 cells displayed a heterozygous TCT?TGT
mutation leading to a serine to cystein substitution
(S37C) of a GSK-3b phosphorylation site in b-catenin
protein (Figure 1a). The b-catenin gene was wild type
in other cell lines. To our knowledge, b-catenin gene
status of SK-Hep1, Mahlavu, SNU387, SNU182,
FOCUS and Hep3B has not been reported previously,
but we confirmed wild-type status of b-catenin in
Huh7, PLC/PRF/5 (Alexander), SNU423 and SNU475
cell lines (Satoh et al., 2000), as well as the interstitial
deletion in HepG2 cell line (de La Coste et al., 1998).
On the other hand, in our hands, it was SNU398, but
not SNU449, which displayed a missense b-catenin
mutation, in apparent opposition to previously,
published data (Satoh et al., 2000).
Table 1 compares the status of b-catenin and p53
genes in these cell lines. The great majority of HCC cell
lines (10 of 12; 84%) displayed a p53 mutation, in
contrast to only 2 of 12 (17%) cell lines displaying a b-
catenin mutation. Either p53 or b-catenin was mutated
in these cell lines, except SNU398 cells, which
displayed both p53 and b-catenin mutations, and SK-
Hep1 wild type for both p53 and b-catenin.
Aberrant accumulation of wild-type b-catenin in mutant
p53 cell lines
We analysed all 12 cell lines for a possible accumula-
tion of b-catenin protein by Western blotting. As
shown in Figure 1b, both HepG2 and SNU398
displayed a strong increase in the levels of mutant b-
catenin proteins. Selective accumulation of the mutant,
but not wild-type b-catenin was most evident in HepG2
cell line due to faster migration of truncated b-catenin
(D b-catenin) protein (Figure 1b). As expected, SK-
Hep1 cells expressed wild-type b-catenin at low levels.
On the other hand, all remaining cell lines (n=9)
displayed increased levels of wild-type b-catenin
protein (Figure 1b). This unexpected accumulation of
wild-type b-catenin was as important as the accumula-
tion of mutant b-catenins (compare lanes 2 – 10 with
lanes 11 and 12 in Figure 1b). We also compared
cytosolic and non-cyotosolic forms of b-catenin in
selected cell lines. The accumulation was evident in
both cytosolic and non-cyotosolic forms of wild-type b-
catenin, similarly to mutant forms, in four cell lines
tested, with the exception of Huh7, which displayed an
accumulation of non-cyotosolic b-catenin only (Figure
1c). A closer examination of the wild-type b-catenin
protein levels in comparison to p53 status in these cell
lines revealed a perfect correlation between p53 gene
mutation and b-catenin protein accumulation (Figure
1b and Table 1). This observation led us to hypothesize
that p53 mutations may lead to aberrant accumulation
of wild-type b-catenin protein in cancer cells.
Ectopic expression of mutant p53 causes the accumulation
of wild-type b-catenin protein
To test whether p53 mutation is a direct cause of wild-
type b-catenin accumulation in HCC cells, we
Table 1 Comparative analysis of p53 and b-catenin status of
hepatocellular carcinoma
b-catenin b-catenin
Cell lines p53 gene gene protein levels
SK-Hep1 w.t. w.t. Low
HepG2 w.t. w.t. Low
D25-140 Increased
Huh7 Y220C w.t. Increased
SNU449 K139R w.t. Increased
A161T
SNU387 L164X w.t. Increased
Mahlavu R249S w.t. Increased
SNU182 S215I w.t. Increased
FOCUS 7/7 w.t. Increased
Hep3B 7/7 w.t. Increased
PCL/PRF/5 R249S w.t. Increased
SNU475 N239D w.t. Increased
C275R
N288S
SNU398 7/7 w.t./S37C Increased
w.t., wild type; 7/7, gene deletion and/or protein loss. Data on the
status of p53 gene in SK-Hep1, HepG2, Hep 3B, PLC/PRF/5 and
Huh7 has been previously reported (Sayan et al., 2001a), data for
SNU475, SNU449, SNU387 and SNU182 was obtained from the
IARC p53 mutation database version R6 (http://www.iarc.fr/p53/
Index.html; Olivier et al., 2002)
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generated several stable clones following transfection of
wild-type p53-expressing HepG2 cell line with mutant
p53 expression plasmids. HepG2-143, HepG2-248 and
HepG2-249 clones expressing mutant p53-V143A, p53-
R248W and p53-R249S proteins respectively, displayed
an increase in the wild-type b-catenin levels, with no
apparent change in the levels of mutant D b-catenin
protein (Figure 2a). Time- and temperature-dependent
comparison of parental HepG2 and clonal HepG2-143
cells confirmed that wild-type b-catenin protein levels
were consistently higher in mutant p53-expressing cells,
in comparison to parental cell line (Figure 2b). This
Figure 1 (a) b-catenin mutation status of hepatocellular carcinoma cell lines. Direct sequencing of exon 3 and fragment length
analysis of exons 2 – 4 of genomic DNAs from 12 cell lines showed a point mutation in SNU398 (top), but not in other cell lines
(SK-Hep1 data shown as an example). Data for HepG2 with a partial deletion of b-catenin gene which has previously been reported
by de La Coste et al. (1998) was shown in Figure 3a. (b) Increased b-catenin protein levels in HCC cell lines displaying a p53 muta-
tion. Western blot assay for b-catenin protein shows that wild-type p53-expressing cell lines SK-Hep1 (lane 1) and HepG2 (lane 12)
express low levels of wild-type b-catenin protein. The truncated mutant b-catenin (D b-catenin) observed in HepG2 (lane 12) and
non-truncated mutant b-catenin in SNU398 (lane 11) serve as examples of stabilized mutant b-catenin proteins. In contrast, all mu-
tant p53 cell lines (Table 1) shown in lanes 2 (Huh7), 3 (SNU449), 4 (SNU387), 5 (Mahlavu), 6 (SNU182), 7 (FOCUS), 8 (Hep3B),
9 (PLC/PRF/5), and 10 (SNU475) display increased levels of wild-type b-catenin protein. GSK-3b serves as a protein loading con-
trol. (c) Both cytosolic and non-cytosolic fractions of b-catenin are increased in mutant p53 cell lines (Mahlavu, Hep3B and PLC/
PRF/5), except Huh7 which displays an increase in non-cytosolic fraction only
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data also showed that the increase in b-catenin levels
was independent of conformational change of p53-
V143A protein at 328C (Figure 2b; Friedlander et al.,
1996). We also generated stable clones from wild-type
p53-expressing cell line SK-Hep1, following transfec-
tion with either p53-V143A or pCDNA3A plasmid. As
shown in Figure 2c, cells which were stably transfected
with mutant p53 plasmid, but not those transfected
with a control plasmid, displayed a modest but
consistent increase in wild-type b-catenin protein levels.
This effect was observed in all three p53-V143A-
expressing clones tested.
As an additional test, we stained HepG2 and SK-
Hep1 clones for b-catenin by immunofluorescence. As
shown in Figure 3, SK-Hep1-143-2 clone, which
express the mutant p53-V143A protein, displayed
strong nuclear b-catenin staining, as opposed to the
SK-Hep1 – pCDNA3A negative control clone. HepG2
cell line with endogenously mutated b-catenin gene also
showed strong nuclear b-catenin staining (data not
shown), as reported previously (de La Coste et al.,
1998; Satoh et al., 2000). HepG2 clones expressing
mutant p53 displayed the same type of b-catenin
staining (data not shown).
We also tested whether the increase in b-catenin
protein levels following p53 inactivation was due to an
increase in gene transcription. As shown in Figure 4,
semi-quantitative RT–PCR analysis of b-catenin
transcripts indicated that full-length b-catenin cDNA
transcripts encoding for wild-type b-catenin were
higher in HepG2 clones, in comparison with those
observed in the parental cell line. Interestingly, we did
not observe an increase in truncated b-catenin cDNA
(Db-catenin) levels under the same conditions. Thus, it
appears that the inhibition of wild-type p53 in these
cells results in an increase in transcripts encoding for
wild-type b-catenin protein. A moderate increase in
wild-type b-catenin transcript levels was also observed
in SK-Hep1-derived clones (data not shown).
These additional observations suggested that p53
mutation plays a key role in the aberrant accumulation
of b-catenin in cancer cells. To further elaborate on
this hypothesis, we compared p53 and b-catenin
mutation frequencies in primary tumors.
b-catenin mutations are rare in primary tumors from
southern Africa and China
Hepatocellular carcinomas from southern Africa and
China are known for their high frequency of p53
mutations, mostly affecting codon 249 (Bressac et al.,
1991; Hsu et al., 1991, Ozturk et al., 1991). We tested
genomic DNAs from 33 tumor samples from these
geographical locations for possible mutations affecting
b-catenin gene, by SSCP and DNA sequencing of exon
3, and by size testing of a region encompassing exons
2 – 4, following PCR amplification of genomic DNA.
All tumor samples displayed wild-type b-catenin
sequences at exon 3 (data not shown) and there was
no deletion-type mutation within the exon 2 – 4 region
(Figure 5a).
Inverse correlation in the worldwide distribution of b-
catenin and p53 gene mutations in hepatocellular
carcinoma
The apparent lack of b-catenin mutations in our tumor
samples from southern Africa and China was in sharp
contrast with high frequency of mutations reported for
tumors from other regions of the world (Buendia,
2000). Based on our previous work, which demon-
strated that the mutation rates of p53 differ
significantly from one geographical region to another
(Unsal et al., 1994; Ozturk, 1999), we compared
reported b-catenin mutation rates in HCCs from
different countries. Based on data collected from 1123
Figure 2 (a) Ectopically expressed mutant p53 proteins cause an
increase in the levels of wild-type b-catenin, but not truncated b-
catenin (D b-catenin) in HepG2-derived stable clones. HepG2-143,
HepG2-248 and HepG2-249 express mutant p53-V143A, p53-
R248W and p53-R249S proteins, respectively. (b) Increase of
wild-type b-catenin levels in clone HepG2-143 is independent of
time and temperature. Cells were left 18 h after plating at 378C,
then the incubation temperature was shifted to 328C in one set
of plates, and b-catenin was tested at times 0, 8 and 12 h by Wes-
tern blotting. (c) Ectopic expression of mutant p53-V143A leads
to an increase in wild-type b-catenin protein levels in SK-Hep1
cells. SK-Hep1-143-2, SK-Hep1-143-3 and SK-Hep1-143-8 clones
were generated following stable expression of mutant p53-V143A,
whereas SK-Hep1 – pCDNA3 clone was obtained following trans-
fection with empty control vector. GSK-3b serves as an equal
protein loading control in a, b and c
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tumor samples, overall mutation rate of b-catenin in
HCC was 17%, but its geographical distribution was
highly heterogeneous. The lowest mutation rate was
seen in tumors from Africa (0%), followed by China
(9%), Japan (19%) and Europe (24%), which
displayed the highest mutation rate. A similar analysis
of p53 mutation frequencies showed that the overall
p53 mutation rate in 969 tumors was 27%. The highest
mutation frequency was observed in tumors from
Africa (42%), followed by China (38%), Japan (27%)
and Europe (15%), which displayed the lowest
mutation rate (Table 2). As illustrated in Figure 5b,
p53 and b-catenin mutation rates in HCC follow a
perfect but inverse occurrence pattern. This pattern is
characterized by a dominant p53 mutation frequency in
tumors from Africa and China, associated with a low
Figure 3 Nuclear accumulation of b-catenin in SK-Hep1 cells following ectopic expression of mutant p53 protein p53-V143A. The
negative control clone SK-Hep1 – pCDNA3 (a – f) and mutant p53 expressing clone SK-Hep1-143-2 (g – i) were subjected to immu-
nofluorescence staining for b-catenin. Compared to antibody negative control (a – c), staining of SK-Hep1 – pCDNA3 with anti-b-
catenin antibody (d – f) showed diffused cytoplasmic staining with weak nuclear staining (e,f). In contrast, strong nuclear b-catenin
staining was evident with SK-Hep1-143-2 clone (h,i). Fixed and permeabilized cells were subjected to nuclear DNA (a,d,g) and im-
munofluorescence staining (b,e,h), and then digital pictures were merged (c,f,i)
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rate of b-catenin mutations. In tumors from other
geographical regions, b-catenin mutations are more
prominent, or even more frequent than p53 mutations,
as observed in tumors from Europe (Figure 5b).
Discussion
Aberrant accumulation of b-catenin has been observed
in different types of tumors. This accumulation is
usually due to a defective proteosomal degradation of
b-catenin, which may result from mutations affecting
b-catenin, APC or Axin1 gene, depending on cancer
type (Polakis, 2000). Here, we report that aberrant
accumulation of b-catenin is also associated with p53
mutations. The reasons for this association are not
known presently. However, two types of studies have
established the presence of a functional cross-talk
between p53 and b-catenin. Recently, it has been
reported that wild-type p53 is able to induce the
expression of Siah-1 gene, which encodes a protein
involved in the ubiquitin-mediated degradation of b-
catenin protein. Accordingly, wild-type p53-induced
Siah-1 was shown to down-regulate b-catenin levels
(Liu et al., 2001; Matsuzawa and Reed, 2001).
However, it is unknown whether mutational inactiva-
tion of p53 may cause a loss of basal Siah-1
expression leading to defective b-catenin degradation.
Using a semi-quantitative RT –PCR assay, we
observed that all HCC cell lines tested here express
Siah-1 transcripts independent of p53 status, with the
exception of SK-Hep1 cells which display extremely
low levels. In addition, Siah-1 transcripts appeared not
to be modified in HepG2 and SK-Hep1 clones
expressing mutant p53 protein (both data not shown).
Therefore, the accumulation of b-catenin in mutant
p53 cell lines may not be related to loss of Siah-1
activity. On the other hand, oncogenic activation of b-
catenin was shown to serve as a stimulus for
activation of wild-type p53 activity, which induces
Figure 4 Up-regulation of wild-type b-catenin transcripts in
HepG2 cells following ectopic expression of mutant p53 proteins
p53-V143A, p53-R248W and p53-R249S proteins, respectively.
Total cellular RNAs were analysed by semi-quantitative RT–
PCR. Note that full-length b-catenin (top), but not truncated
Db-catenin transcripts are increased in mutant p53 expressing
clones, in comparison with parental HepG2 cell line. GADPH
was used as a PCR loading control Figure 5 Worldwide distribution of p53 and b-catenin mutation
frequencies in hepatocellular cancers. (a) Absence of b-catenin
mutations in HCCs from southern Africa (n=22) and China
(n=11). Picture shows that a region of b-catenin gene (exons
2 – 4) known to be deleted in some cancers is devoid of truncating
mutations in 12 HCCs from southern Africa, as an example.
Genomic DNA from HepG2 cell line was used as a positive con-
trol for deletion (*). All 33 tumor samples were also tested by
SSCP and direct sequencing, but no mutation was found (data
not shown). (b) Comparative analysis reveals an inverse relation-
ship between worldwide rates of p53 and b-catenin mutations in
hepatocellular carcinoma. p53 and b-catenin mutations in tumors
from different geographical locations (reported here and complied
from previous reports by others) were calculated as shown in Ta-
ble 2, and represented as a comparative graph here. Note that in
tumors from Western populations, p53 mutations are rare, while
b-catenin mutation rate is high. Inversely, b-catenin mutations are
rare in tumors from Africa and China which display high rate of
p53 mutations
Table 2 Geographical distribution of reported b-catenin and p53
mutation rates in hepatocellular carcinoma
Region b-catenin p53
Africa 0/22 (0%) 11/26 (42%)
Chinaa 12/133 (9%) 50/132 (38%)
Japan 44/241 (19%) 94/353 (27%)
Europe 26/108 (24%) 23/151 (15%)
Otherb 102/619 (17%) 79/273 (28%)
All 184/1123 (17%) 263/969 (27%)
aMainland China and Hong Kong, bAustralia, North America,
Singapore, South Korea, Taiwan, Thailand, or unidentifiable origin.
b-catenin data is a combination of the data presented here (data for
Africa and part of China), and those compiled from references
Devereux et al., 2001, Wong et al., 2001 (for China); Miyoshi et al.,
1998; Kondo et al., 1999; Satoh et al., 2000; Fujie et al., 2001 (for
Japan); Nhieu et al., 1999; Terris et al., 1999 (for Europe); Huang et
al., 1999; Hsu et al., 2000; Laurent-Puig et al., 2001; De La Coste et
al., 1998 (for other). p53 data is from Ozturk, 1999
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cell cycle arrest or apoptosis as a response (Damalas
et al., 1999, 2001). Therefore, the mutant b-catenin
and wild-type p53 activity may not be compatible for
cell survival, so that p53 gene is also mutated during
tumor progression following b-catenin mutation. This
appears to be the case in colorectal cancers where
early oncogenic activation of b-catenin (either directly
by b-catenin mutation, or indirectly by APC muta-
tion) is followed by a sharp increase in p53 mutation
frequency (Kinzler and Volgelstein, 1998). The same
mechanism could also be involved in some HCCs
displaying both p53 and b-catenin mutations such as
SNU398 cell line, but most HCC cell lines have either
p53 or b-catenin mutation (Table 1). Oncogenic
activation of wild-type b-catenin in HCC by muta-
tions affecting APC and Axin1 gene is also
conceivable. As stated earlier, APC mutation is
exceptional in HCC, while Axin1 mutation appears
to affect less than 10% of these tumors. In HCC cell
lines studied here, PLC/PRF/5, SNU423 and SNU475
have been reported to display Axin1 mutation, while
Huh7 had no mutation (Satoh et al., 2000). So far, we
were able to confirm the Axin1 status of these cell
lines, but we failed to identify any Axin1 mutation in
the remaining nine cell lines (data not shown). Thus,
we believe that in most HCC cell lines, the
accumulation of b-catenin occurs as a consequence
of functional inactivation of p53. Induced accumula-
tion of wild-type b-catenin in HepG2 and SK-Hep1
cells following ectopic expression of mutant p53
proteins provides additional evidence for our hypoth-
esis. The increase in wild-type b-catenin levels in
mutant p53-expressing clones of HepG2 and SK-Hep1
was modest, but this is probably due to the fact that
these clones still express wild-type p53, in contrast to
other cell lines, which have complete loss of wild-type
p53 allele (Table 1). Nuclear accumulation of b-
catenin is considered as an indication of its aberrant
accumulation in cells, in particular due to APC
mutations in colorectal cancers (Handerson, 2000;
Polakis, 2000). We have shown wild-type b-catenin
accumulation in the nuclei of SK-Hep1 cells, following
p53 inactivation (Figure 3). Thus, it appears that p53
inactivation, similar to APC or Axin1 inactivation
leads to oncogenic activation of b-catenin in cancer
cells. This activation appears to be due, at least in
part, to an up-regulation of wild-type b-catenin
transcripts, as demonstrated in HepG2 cells (Figure
4). Interestingly, p53 status did not affect truncated
Db-catenin transcripts in the same cell line (Figure 4).
The reasons of this differential response are presently
unknown. However, this could be due to allele-specific
interstitial b-catenin gene deletion in HepG2 cells,
which may abolish the ability of this gene to respond
to wild-type p53. This hypothesis remains to be
demonstrated experimentally.
The p53 gene is one of the most frequently mutated
or inactivated genes in hepatocellular, breast, lung and
cervix cancers which express aberrantly accumulated
b-catenin protein that can not be explained solely by
b-catenin, APC or Axin1 gene mutations. Thus, it is
highly likely that, the loss of p53 function is a
considerable cause for aberrant accumulation of b-
catenin in these tumors. Presently, it is unclear
whether p53 mutation may serve as an alternative
mechanism for oncogenic activation of b-catenin
during tumor development. Such a hypothesis could
be indirectly verified by testing whether p53 and b-
catenin mutations are mutually exclusive, as it has
been shown for APC and b-catenin mutations in
colorectal cancers (Sparks et al., 1998). Data presented
in Table 1 indicate that p53 and b-catenin mutations
are mutually exclusive in 11 of 12 (92%) of HCC cell
lines. We were not able to address this issue in
primary tumors, but Figure 3b shows that overall
frequencies of p53 and b-catenin mutations show an
inverse correlation in HCCs from different geographi-
cal locations, as if these mutations are mutually
exclusive in these tumors. A careful examination of
previously published data on p53 and b-catenin
mutations provides additional hints for a close
connection between p53 and b-catenin in different
HCC models. For example, data published by
Laurent-Puig et al. (2001) show that p53 and b-
catenin mutations are mutually exclusive in 58 of 62
(94%) of primary HCC tumors, and only 4 of 62
(7%) of tumors display mutations on both genes. In
another study, Renard et al. (2000) reported that
either wild-type p53 allele was lost or b-catenin gene
mutated in HCCs observed in N-myc transgenic mice
that are heterozygous for p53 gene. It is also
noteworthy that b-catenin mutations were shown to
be absent in HCCs that occur in SV40 Large T
transgenic mice (Umeda et al., 2000), whereas b-
catenin is mutated frequently in other models of
experimentally induced mouse HCCs (de La Coste et
al., 1998; Calvisi et al., 2001). Transforming ability of
large T antigen is known to be due, at least partly, to
functional inactivation of p53 (Pipas and Levine,
2001). Therefore, the lack of b-catenin mutation in
these tumors could be due to a functional activation
of its protein product by large T antigen via p53
inactivation.
Taken together, these observations clearly indicate
that b-catenin mutations occur rarely in cancer cells
which have lost wild-type p53 function, but these cells
display aberrant accumulation of wild-type b-catenin
protein. These findings may strengthen a hypothesis
linking p53 mutations to oncogenic activation of b-
catenin, even though this has to be demonstrated
experimentally. If this is the case, critical target genes
of activated b-catenin must be induced in cancer cells
following p53 inactivation. This demonstration will not
be an easy task for HCC, since best described b-catenin
targets, namely cyclin D1 and c-myc (He et al., 1998;
Tetsu and Mccormick, 1999) appear not to be involved
in b-catenin-mediated hepatocellular carcinogenesis.
For example, neither c-myc nor cyclin D1 is over-
expressed in hyperplastic livers of transgenic mice,
which develop hepatomegaly as a result of oncogenic
b-catenin overexpression (Cadoret et al., 2001).
Furthermore, Inagawa et al. (2002) did not find any
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association between accumulation of b-catenin and
overexpression of cyclin D1 in human HCCs. In
confirmation of these observations, we did not detect
any correlation between c-myc/cyclin D1 protein over-
expression and b-catenin mutation or b-catenin
accumulation in 12 HCC cell lines studied here (data
not shown). Thus, it appears that b-catenin acts on
targets other than c-myc and cyclin D1 to exhibit its
oncogenic activity in liver cells. Some genes whose
over-expression is associated with p53 mutation in
cancer cells could be such targets for b-catenin in liver
cells.
In conclusion, both p53 and wnt pathways are
involved in many cellular processes independent of
each other (Barker et al., 2000; Polakis, 2000; Ryan et
al., 2001). Nevertheless, there is now sucient evidence
for a functional cross-talk between p53 and wnt
pathways (Damalas et al., 1999, 2001; Liu et al.,
2001; Matsuzawa and Reed, 2001; Sadot et al., 2001
and this study). Studies aiming to explore combined
effects of p53 and wnt pathway deregulations may open




Twelve HCC cell lines and 33 primary HCCs from patients
who lived in southern Africa (n=22) and China (n=11) were
analysed. Genomic DNAs were isolated as described
previously (Unsal et al., 1994; Yakicier et al., 1999). The
exon 3 sequence of b-catenin was studied for base
substitutions and small insertion/deletions by SSCP as
described previously (Ozdag et al., 2000), as well as by direct
DNA sequencing. In addition, the b-catenin gene region
encompassing exons 2 to 4 was studied for larger deletions,
essentially as described by Koch et al. (1999). Sequencing was
performed in both direction and reaction products were run
on an ABI Prism 377 DNA Sequencer (Applied Biosystems,
USA), and the sequencing data was analysed with ABI Prism
Sequencing Analysis 3.3 software (Applied Biosystems).
Cell lines and construction of stable clones
The origins and culture conditions of HCC cell lines used
here have been reported recently (Sayan et al., 2001a).
HepG2 and SK-Hep1 cell line clones ectopically expressing
mutant forms (p53-V143A, p53-R248W, p53-R249S) of p53
were generated by stable transfection with appropriate
plasmids (Frebourg et al., 1992), as described previously
(Ponchel et al., 1994). An empty pCDNA3A plasmid
(Invitrogen, USA) was used to generate negative control
clones.
Preparation of cell lysates and western blotting
Detergent-soluble cell lysates were prepared and used for the
analysis of total b-catenin and p53 protein levels by western
blot assay, as described previously (Sayan et al., 2001a).
Cytosolic and non-cytosolic forms of b-catenin were analysed
on protein lysates prepared from corresponding cellular
fractions. These fractions were prepared as described by Iwai
et al. (1995), with some modifications. Briefly, culture
medium was removed and cells were washed twice with ice-
cold PBS, scraped and resuspended in 2 ml sucrose buffer.
After 20 strokes in glass homogenizer, the samples were
centrifuged at 100 000 g for 1 h and supernatants were
collected as cytosolic fraction. The pellet was resuspended
in 2 ml sucrose buffer to obtain non-cytosolic fraction. Equal
volumes from both fractions were solubilized in SDS sample
buffer and used for SDS-polyacrylamide gel electrophoresis.
Antibodies to b-catenin (clone E5 from Santa Cruz Biotech.
USA) and GSK-3b (clone 7 from Transduction Labs., USA)
were obtained commercially. The anti-p53 monoclonal anti-
body 6B10 was described previously (Yolcu et al., 2001). In
order to generate a linear response in Western blotting
assays, we used appropriate amounts of proteins from cell
lysates for SDS –PAGE and an ECL kit (Amersham
Pharmacia Biotech, UK) for detection of antigen-antibody
complexes. Equal protein loading was verified by Western
blot assay with GSK-3b whose levels are known to be stable
in quiescent and proliferating hepatocytes (Monga et al.,
2001). Experiments were repeated several times with different
batches of cell lysates for verification.
Immunofluorescence staining for b-catenin
Cells were stained as described previously (Sayan et al.,
2001b), by formaldehyde fixation and Triton X-100 permea-
bilization technique, using the anti-b-catenin monoclonal
antibody (Clone 6F9, Abcam), followed by incubation with
FITC-conjugated rabbit anti-mouse antibodies (Dako).
Nuclear DNA was visualized by Hoechst 33258 staining
(Sayan et al., 2001b). Pictures were taken using fluorescence
microscope (Zeiss –Axioskop). Picture was captured in a
digital Kodak Camera (DC 290) using Adobe Photo Deluxe
(adobe System Inc.) software. Images were captured at 4006
and picture was edited using Paint Shop Pro 7.0 (Jasc
Software Inc.).
Semi-quantitative RT –PCR analysis of b-catenin transcripts
Total RNA was extracted and used for cDNA synthesis and
semi-quantitative RT–PCR analysis, as described previously
(Sayan et al., 2001a), using a b-catenin primer pair derived
from exons 2 and 4, respectively (Koch et al., 1999), allowing
to detect differentially the expression of wild-type and
truncated b-catenin transcripts in HepG2 cells which displays
a heterozygous interstitial deletion of b-catenin gene between
exons 2 and 4 (de La Coste et al., 1998).
Analysis of worldwide distribution of p53 and b-catenin
mutations
Using data generated in this work (n=33), as well as data
compiled from previous reports by different authors, we
calculated mutation frequencies of b-catenin in a total of
1123 hepatocellular carcinoma samples from different
geographical locations. p53 mutation frequencies for 969
tumor samples were taken from our earlier report (Ozturk,
1999).
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